中国医疗体系的营业额在2024年下降了6.8%,但创新药品的销售额上升了4.1%,推动了未来增长计划。 China Medical System's turnover fell 6.8% in 2024, but sales of innovative drugs rose 4.1%, driving future growth plans.

由于国家量基采购,中国医疗系统(CMS)的营业额在2024年下降了6.8%,降至74.69亿元。 China Medical System (CMS) saw a 6.8% drop in 2024 turnover to RMB7,469 million due to National Volume Based Procurement. 不过,独家和创新药品销售额上升了4.1%,达到45.51亿元,占总收入的52.8%。 However, sales of exclusive and innovative drugs rose 4.1% to RMB4,551 million, accounting for 52.8% of total revenue. CMS提交了两份新药品的NDA,包括一份用于维蒂里戈的药品,并拥有近40种创新输油管产品。 CMS submitted NDAs for two new drugs, including one for vitiligo, and has nearly 40 innovative pipeline products. 该公司还正在扩大其东南亚的业务,并侧重于全球一流和一流药品,以推动未来的增长。 The company is also expanding its Southeast Asia business and focusing on global first-in-class and best-in-class drugs to drive future growth.